Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oncovir
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Thailand, United States
Active Clinical Trial Count: 9
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: HIV Infections|Oncology Solid Tumor Unspecified|Prostate Cancer
Phase 1: Bladder Cancer|COVID-19|Glioma|Mesothelioma|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06614140 |
SQK01-001 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-08-15 |
22% |
2024-09-27 |
|
NCT05111353 |
NCT05111353 | P1 |
Completed |
Pancreatic Cancer |
2025-11-03 |
2025-11-06 |
Primary Endpoints|Treatments|Trial Status |
|
NCT01130077 |
STUDY19040319 | P1 |
Completed |
Glioma |
2024-11-01 |
2024-12-07 |
||
NCT04672291 |
ONV2020-003 | P1 |
Completed |
COVID-19 |
2023-04-01 |
11% |
2023-05-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |
NCT04345705 |
GCO 19-2701 | P1 |
Not yet recruiting |
Mesothelioma |
2022-05-01 |
88% |
2020-04-15 |
Primary Endpoints|Treatments |
NCT06529822 |
NCT06529822 | P1 |
Recruiting |
Bladder Cancer |
2028-10-31 |
12% |
2026-01-14 |
|
2015-000511-40 |
2015-000511-40 | P2 |
Active, not recruiting |
HIV Infections |
2022-08-13 |
2022-03-13 |
Treatments |
|
NCT06343077 |
STUDY-22-00106 | P2 |
Recruiting |
Prostate Cancer |
2026-12-31 |
26% |
2024-04-03 |
Primary Endpoints|Treatments |
NCT05013216 |
J2177 | P1 |
Recruiting |
Pancreatic Cancer |
2027-10-01 |
2025-08-27 |
Primary Endpoints|Treatments |